HeartBeam Wins Industry Innovation Award for Advancing Remote Cardiac Care With Groundbreaking ECG Technology
The Medical Device Network Excellence Awards, powered by GlobalData's business intelligence, is one of the most respected independent recognition programs in the industry. The program analyzes over one billion datasets annually to recognize forward-thinking companies that drive positive change and set new standards for excellence across the global medical device sector.
The award recognizes HeartBeam's proprietary 3D ECG technology which captures the heart's electrical signals in 3 distinct, non-coplanar directions and then synthesizes these signals into a 12-lead ECG. The technology makes it possible to provide diagnostic fidelity similar to a standard 12-lead ECG in a credit card-sized, cable-free device which enables patients to record their arrhythmia symptoms the moment they occur. The 12-lead ECG synthesis software is currently under review by FDA, and upon FDA clearance, HeartBeam plans to initiate commercialization.
'This recognition affirms our vision of transforming how cardiac conditions are monitored and detected and validates our belief that access to high-fidelity ECG data should not be limited by healthcare settings,' said Robert Eno, Chief Executive Officer of HeartBeam. 'As we continue to prepare for the market introduction of the HeartBeam System, this award highlights our leadership position in delivering clinically validated, patient-centric solutions to advance remote cardiac care.'
The Medical Device Network Excellence Award adds to the growing body of industry recognitions HeartBeam has received, including the Pinnacle Healthcare Award, Digital Health Hub Foundation Award, and MedTech Breakthrough Award.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024. The 12-Lead ECG synthesis software is under FDA review. The Company holds over 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Cleared Indications for Use
The HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient's 3-Lead (in three-directions) electrocardiogram (ECG) acquired from 5 electrodes. The device is intended to be used by adult patients in either a clinical setting or at home. The device does not conduct cardiac analysis and can be used with an ECG Viewer software system for manual interpretation of non-life-threatening arrhythmias by a physician or healthcare professional. For full safety information, see the full Instructions for Use or Clinician Portal Manual.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
20 minutes ago
- Business Wire
RCKT Deadline: Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025. Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) RP-A501 was less effective than defendants had led investors to believe; (2) to increase its effectiveness, Rocket Pharmaceuticals amended RP-A501's clinical trial protocol by introducing a novel immunomodulatory agent; (3) the foregoing increased the risk that patients would suffer from a Serious Adverse Event ('SAE'); (4) accordingly, RP-A501's safety, as well as its clinical, regulatory, and commercial prospects, were overstated; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Rocket Pharmaceuticals, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 11, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
Yahoo
an hour ago
- Yahoo
The Ocean Floor Could Power EVs. Will This Company Reap the Rewards?
Key Points The Metals Company is developing tech to harvest metal-rich nodules from the ocean floor. The company has no revenue and is still awaiting regulatory approval to begin mining. A recent U.S. permit application could offer The Metals Company an alternative path forward. 10 stocks we like better than TMC The Metals Company › Imagine diving into the Pacific Ocean's depths, not to see coral reefs or look for sunken pirate treasure, but to gather metal-dense rocks containing materials that can power the electric vehicle (EV) revolution. That, in a nutshell, is the bold vision of The Metals Company (NASDAQ: TMC), a Vancouver-based company aiming to vacuum polymetallic nodules from the seafloor. With a stock that had soared 430% in 2025 as of market close July 31, TMC has caught the eyes of investors betting on a future of green energy. But with no revenue, mounting losses, and a sea of risks, is this materials stock worth diving into? Let's explore. What does The Metals Company do? TMC isn't your typical mining stock. The company's core mission is to harvest polymetallic nodules from a remote stretch of Pacific Ocean known as the Clarion Clipperton Zone (CCZ). These lumpy, fist-sized seafloor stones are loaded with nickel, copper, cobalt, and manganese, all essential ingredients in everything from electric vehicle batteries to solar panels. On land, these rare earth metals are mined and processed in carbon-heavy ways, which ironically undercut the clean-tech future many are destined to be part of. TMC wants to flip the script. Instead of digging holes in the earth, it wants to scoop metal-rich nodules from the seabed and refine them into battery-grade materials, possibly with a lighter environmental footprint. The potential for TMC's mining operations is huge. As Henry Sanderson points out in his book Volt Rush: The Winners and Losers in the Race to Go Green, the deep sea holds more nickel, cobalt, and possibly other rare earth metals than all the world's land-based reserves combined. The CCZ alone is believed to contain some 21 billion metric tons of nodules -- enough raw material to not only shake China's grip on battery metals but supercharge the EV revolution for decades, if the materials can be gathered and refined. A big vision, but zero revenue But let's not sugarcoat it: TMC is nowhere near harvesting nodules at a commercial scale. The company reported zero revenue in the first quarter of 2025, paired with a net loss of about $20.6 million. That loss widened from $16.1 million in the quarter before. It turns out that building an underwater mining infrastructure from scratch isn't going to be cheap. Or quick. As of writing, TMC still doesn't have the green light to mine commercially in the CCZ. Although it holds exploration rights across two massive patches there, it doesn't yet have permission to start harvesting the goods. That authority rests with the International Seabed Authority (ISA), a United Nations-backed body that still hasn't finalized the regulatory playbook that companies like TMC need to operate. But there's a plot twist with the ISA: The U.S. never ratified the treaty that made the agency. While 169 nations and the European Union formally recognize the agency's authority, the U.S. isn't one of them. True, it does acknowledge parts of the treaty as international law, but technically, it's not bound by the ISA's rulebook. This means that if national interest comes into play -- say, securing domestic access to critical minerals -- the U.S. could try to go its own way. That would give companies like TMC a potential fast track to start operating in the CCZ. This is exactly the door that TMC is trying to walk through. In April 2025, the company filed a permit application under a decades-old U.S. law just days after President Donald Trump signed a U.S. executive order renewing interest in offshore critical minerals. If TMC's application is approved, it could mean mining under American jurisdiction in waters considered off-limits to the rest of the world. It's a long shot, legally speaking, and could breach international norms, but it would be a major breakthrough for a company with no revenue. A long-term wager with caveats TMC is what I'd call a moonshot (or, maybe a deep-sea Hail Mary) -- it's a big idea with big risks and potentially big payoffs. If the permits come through and the tech scales, today's price could look like a bargain. After all, a $2.65 billion market cap could look small compared to the multitrillion-dollar demand for battery metals that's expected over the next few decades. If TMC becomes even a minor supplier in that chain, its top-line growth could dwarf what investors are paying today. But if the ISA blocks its permit, or if U.S. jurisdiction doesn't hold up to legal scrutiny, or if other things turn out in ways not the best for the company, TMC could keep burning cash with no clear path to revenue. That's a lot of "ifs." Clearly, this isn't a stock for the risk-averse. For aggressive investors with long-term horizons, a small stake might make sense as part of a diversified portfolio. But I would wait for tangible progress, like a confirmed mining license, before scaling up exposure. Should you buy stock in TMC The Metals Company right now? Before you buy stock in TMC The Metals Company, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TMC The Metals Company wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Steven Porrello has positions in TMC The Metals Company. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The Ocean Floor Could Power EVs. Will This Company Reap the Rewards? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Synaptigen Introduced as Natural Brain Support Option for Aging Adults in 2025
Clinically-Inspired Daily Formula Highlights Cognitive Clarity, Focus, and Mental Energy for Adults Over 50 New York, Aug. 02, 2025 (GLOBE NEWSWIRE) -- This press release is for informational purposes only. The statements below are not medical advice and have not been evaluated by the Food and Drug Administration (FDA). Synaptigen is not intended to diagnose, treat, cure, or prevent any disease. Some links included in this release may be affiliate in nature. See full disclaimer at the end. Synaptigen Introduced as Natural Brain Support Option for Aging Adults in 2025 A New Plant-Based Formula Aims to Support Memory, Mental Agility, and Neuronal Clarity Without Stimulants In 2025, a new pineal-focused supplement called Synaptigen is gaining widespread attention among adults seeking cognitive clarity and long-term brain health. At a time when digital burnout, information overload, and lifestyle-related inflammation are on the rise, this daily-use capsule supports mental clarity and focus without using stimulants or synthetic nootropics. The formula uses a blend of probiotic strains, botanical extracts, and prebiotic fibers to help nourish the brain from within—an approach that aligns with recent neuroscience linking the gut microbiome to cognition, emotional regulation, and memory performance. Formulated to be stimulant-free, Synaptigen offers a gentler daily option for those looking to promote brain wellness well into old Interest in 'A Breakthrough Natural Solution That Supports A Healthy Memory Well Into Old Age' Is Surging in 2025 The global surge in cognitive wellness awareness is no longer limited to older adults. In 2025, younger generations are taking proactive steps toward preserving mental clarity—driven by trends on TikTok, neuroscience podcasts, and global wellness data. Google Trends shows a steep climb in searches for "pineal gland detox," 'gut-brain axis,' and 'mental fog remedies' over the past 18 months, pointing to a cultural shift in how people perceive brain health. Meanwhile, studies on microbiome influence over memory and focus have been widely shared in mainstream media. The connection between sugar accumulation in neurons and early cognitive decline—sometimes referred to as 'Type 3 Diabetes' in research circles—has caught public attention. Individuals are actively seeking natural ways to combat this silent cognitive erosion, especially through ingredients like inulin, peppermint, and specific strains of probiotics. Synaptigen addresses this demand with a plant-based, gut-brain support approach that avoids stimulants, synthetic nootropics, or sedative herbs. By blending modern nutritional science with microbiome-targeted delivery, it appeals to wellness-focused consumers who want long-term results without side effects. Synaptigen's Ingredient-First Response to These Trends As the conversation around 'natural mental support' grows more nuanced, Synaptigen takes an ingredient-first stance that aligns with consumer demand for transparency and simplicity. Rather than focusing on hype-based trends, the formula was designed around peer-reviewed data linking gut health, inflammation control, and nutrient signaling to memory function and cognitive sharpness. Its inclusion of Lactobacillus paracasei, Lactobacillus reuteri, and Bifidobacterium lactis BL-04 targets gut flora balance—an emerging area of interest among researchers studying Alzheimer's prevention and age-associated memory impairment. Unlike stimulant-based supplements that create short-term energy spikes, Synaptigen focuses on consistent nourishment of the gut-brain axis. Also featured is inulin, a natural prebiotic fiber shown to feed beneficial bacteria and reduce systemic inflammation—an issue many associate with cognitive fatigue. Strawberry extract, peppermint oil, and tricalcium phosphate round out the formula, providing natural support for taste, cellular signaling, and digestive balance. See What Makes Synaptigen's Daily Use Formula Unique Ingredient Spotlight – What's Inside the 'Wealth Resin' Formula Synaptigen's formula is carefully constructed around what the developers describe as a 'Wealth Resin' system—a reference to the foundational role these ingredients play in promoting clarity, cellular communication, and inner calm. The blend is anchored in plant-based, probiotic-forward nutrition rather than synthetic nootropics or aggressive adaptogens. Key inclusions like Lactobacillus paracasei and Lactobacillus reuteri have been shown in animal studies to help modulate blood sugar and promote gut balance, two factors now widely discussed in connection with early memory preservation. Meanwhile, Bifidobacterium lactis BL-04® is supported by published research for its potential in supporting immune signaling, cognitive stress recovery, and healthy inflammatory responses. Inulin, a prebiotic fiber, plays a dual role: it feeds healthy bacteria and may help mitigate sugar-related brain stress. Coupled with tricalcium phosphate, the formula adds a layer of support for neural conductivity. Lastly, strawberry extract and peppermint oil are used not just for palatability—but also for their roles in oxidative stress modulation and calm mental focus. Each capsule is free from stimulants, non-GMO, and designed for easy daily use. It represents a simplified, intuitive format for those seeking clarity without relying on caffeine, racetams, or synthetic compounds. What Reddit, Podcasts & TikTok Creators Are Saying In 2025, consumer health conversations are no longer confined to journals and wellness blogs—platforms like Reddit, TikTok, and Spotify-hosted wellness podcasts have emerged as driving forces behind supplement trends. Synaptigen has organically surfaced in several of these online discussions, not through direct advertising, but as part of broader conversations around pineal gland detox, mental fog, and holistic clarity. On Reddit, threads in communities like r/Biohackers, r/Supplements, and r/Nootropics have increasingly explored natural alternatives to prescription memory enhancers, with users citing ingredients like inulin, Bifidobacterium strains, and peppermint extract as part of their brain-support routines. The microbiome-brain connection is a recurring topic, especially among users seeking cognitive performance without stimulant dependence. Podcasts focused on holistic health and modern neuroscience have echoed these themes. Mentions of neuro-gut connectivity, age-related 'brain burnout,' and the potential role of dietary fibers in memory recall are trending topics. Even TikTok creators in the wellness space—many of whom speak to an audience in their 30s and 40s—have drawn attention to the shift away from synthetic focus aids toward plant-based, probiotic-friendly Might Be Drawn to This Type of Supplementation in 2025 The rising popularity of cognitive health supplements in 2025 is not limited to seniors. In fact, a growing segment of users exploring products like Synaptigen includes midlife professionals, creative workers, health-conscious Millennials, and individuals experiencing burnout symptoms associated with prolonged digital exposure or high-stress environments. Many are seeking solutions for mental sharpness, task-switching fatigue, and long-term cognitive protection without pharmaceutical intervention. Synaptigen's non-stimulant formula appeals to those who are wary of traditional nootropics that rely heavily on caffeine, L-theanine, or synthetic racetams. Additionally, individuals recovering from brain fog related to poor sleep, stress, or high sugar intake may find the formula aligned with their wellness goals. The inclusion of gut-focused probiotics also positions Synaptigen within the broader trend of microbiome support for mood balance and clarity. It may also appeal to spiritual consumers who are exploring pineal gland awakening as part of a holistic lifestyle, given the natural, non-toxic, and anti-inflammatory properties of the included plant-based nutrients. Spiritual Optimization & Pineal Curiosity – 2025 Market Reflections In 2025, the intersection of spirituality, wellness, and neuroscience is more visible than ever. Consumers are not just seeking physical health—they're also exploring tools that support inner clarity, calm awareness, and meditative focus. This has fueled the rise of a supplement subcategory often referred to as 'pineal support' or 'third eye clarity,' where Synaptigen has found cultural resonance. The pineal gland, long regarded in both ancient traditions and modern metaphysical communities as the seat of intuition and circadian rhythm, is gaining renewed attention. On platforms like YouTube and TikTok, interest in pineal gland detox, decalcification, and pineal-activated consciousness has sparked millions of views—often converging with broader wellness habits like grounding, breathwork, and intermittent fasting. While Synaptigen does not position itself as a spiritual supplement, its clean-label formulation—free from fluoride, artificial additives, or sedatives—makes it attractive to users who align cognitive clarity with spiritual hygiene. Ingredients like peppermint and strawberry extract, already known for their antioxidant properties, have also been discussed for their roles in ritual wellness routines. This convergence of brain health and spiritual alignment has helped carve a niche for supplements like Synaptigen that aim to support mental performance and emotional grounding without pharmacological Public Debate Around Ingredients – Signals, Skepticism, and Saturation As the wellness industry continues to evolve in 2025, public skepticism around cognitive supplements remains high—and rightfully so. The category is saturated with overhyped claims, proprietary blends lacking transparency, and trendy ingredients that don't hold up under scrutiny. Consumers are demanding data-backed formulations that prioritize ingredient synergy and measurable outcomes over marketing flash. Within this climate, many ingredients found in Synaptigen—such as Lactobacillus paracasei, inulin, and peppermint extract—have been extensively researched in independent academic settings. However, the use of probiotics for brain health is still emerging in mainstream awareness, prompting questions about effectiveness, dosage reliability, and long-term benefit. While some critics argue that the connection between gut bacteria and cognition is still too early to commercialize, others point to growing scientific consensus around the microbiome's influence on inflammation, memory signaling, and mood regulation. Peer-reviewed trials, including those cited on the official Synaptigen page, offer a foundation for the formula's relevance. What sets Synaptigen apart in a crowded field is its ingredient transparency, modest positioning, and absence of exaggerated medical claims. It invites curiosity rather than convincing—and supports its efficacy through formulation integrity rather than hyperbole. About Synaptigen Synaptigen is a natural daily-use brain support formula designed to promote cognitive clarity, memory retention, and sustained mental energy without relying on stimulants or synthetic nootropics. Developed with a science-forward mindset, the formula blends probiotics, prebiotics, and antioxidant-rich botanicals that support the gut-brain connection—an increasingly researched area in modern nutritional neuroscience. Rather than positioning itself as a cure or quick-fix, Synaptigen is built for long-term use. Its ingredients have been individually studied for their roles in promoting healthy glucose metabolism, reducing neuron-damaging sugar buildup, and supporting microbiome balance. Each capsule is manufactured in a GMP-certified facility, non-GMO, and free from additives commonly flagged by health-conscious users. The product also comes bundled with digital health content designed to complement the supplement's function—including sleep optimization guides and cognitive focus techniques—at no additional charge with qualifying orders. Learn More About Synaptigen's Mission and Formula Design Contact Synaptigen – Daily Brain Support Backed by Microbiome Research Email: contact@ Phone (US): 1-800-390-6035 INT: +1 208-345-4245 Website: This press release is for informational purposes only. The information contained herein does not constitute medical advice, diagnosis, or treatment and has not been evaluated by the Food and Drug Administration (FDA). Synaptigen is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician or qualified healthcare provider before beginning any new supplement, routine, or health program. Some links in this release may be promotional in nature and may lead to third-party websites. The publisher or author may receive compensation through affiliate commissions if a purchase is made through these links. This compensation does not affect the price you pay and helps support continued research and content publication. Results described or implied may not be typical and should not be interpreted as guarantees. Statements made about ingredients or outcomes reflect public discussion and historical usage only, and are not endorsed by medical professionals or regulatory agencies. Always do your own research and make informed decisions. CONTACT: Email: contact@ Phone (US): 1-800-390-6035 INT: +1 208-345-4245Sign in to access your portfolio
